DiagMDS · Towards novel approaches for Myelodysplastic Syndromes diagnosis to Strengthen Research Human Capital with Cross-Sectoral and Interdisciplinary Staff mobility
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2026-10-01 → 2030-09-30
- Финансиране от ЕС
- 1 322 640 €
- Участници
- 17
- Схема
- HORIZON-TMA-MSCA-SE
Линиите свързват координатора с партньорите.
Накратко на български
Миелодиспластичните синдроми се изследват чрез анализ на кръвта, включително генетични промени и метаболити, с помощта на изкуствен интелект. Това помага за създаването на по-точни и неинвазивни методи за диагностика, тъй като сегашните симптоми често се бъркат с анемия.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
The DiagMDS project aims to enhance training and lifelong learning opportunities for research and innovation staff by providing structured, cross-sectoral and interdisciplinary exchanges for mobility-driven skill development. Myelodysplastic syndrome (MDS) is a heterogeneous group of hematopoietic disorders characterised by dysplasia of blood cell lineages, cytopenia, functional abnormalities, and stem cell-derived defects in differentiation, proliferation, and maturation of myeloid lineages. Despite various advances in the field, early and accurate diagnosis remains challenging, as peripheral blood (PB) counts and morphological features overlap with those of anemias. Current diagnostics rely on an integration of PB, bone marrow (BM) findings, karyotyping, and detection of specific mutations via next-generation sequencing. DiagMDS will address this unmet clinical need by developing novel, non-invasive methods for accurate MDS diagnosis in the PB. DiagMDS will study the immune microenvironment, genome architecture, chromatin accessibility, methylation, EVs cargo, mitochondrial DNA and metabolome in PB of MDS patients. The project will then develop novel in silico approaches to obtain patient-specific omic signatures and chromosomal scaffolds. It will utilise AI-based methods for integrating imaging, omics, and clinical data. Following validation of key findings, diagnostic biomarkers/profiles are expected to be defined. The application of such cutting-edge experimental, computational and clinically relevant approaches will significantly contribute to MDS diagnosis, while strengthening staff skills, knowledge transfer, and research excellence.
Оригинален текст от CORDIS (на английски).
Участници
- IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON · AthinaКоординаторГърция
- AFEKTA TECHNOLOGIES LTD · SiilinjarviФинландия
- Bio Inzenering · SkopjeСеверна Македония
- CELLOCK LTD · NicosiaКипър
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisФранция
- COMPANY FOR RESEARCH AND DEVELOPMENT FINGERPRINT DIAGNOSTICS LLC SKOPJE · SKOPJEСеверна Македония
- ENIOS APPLICATIONS IDIOTIKI KEFALAIOUCHIKI ETAIREIA · KALLITHEAГърция
- ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON · ATHINAГърция
- EXELIXIS DIACHEIRISI EREVNAS KAI EPIKOINONIA EE · GERAKAS ATTIKIГърция
- IZMIR BIYOTIP VE GENOM MERKEZI · İzmirТурция
- Ingenix.ai sp. z o.o. · WarsawПолша
- KING'S COLLEGE LONDON · LondonОбединеното кралство
- MERIEL BIOSCIENCES ANONIM SIRKETI · KONAK/IZMIRТурция
- Nuclein DOOEL · SkopjeСеверна Македония
- POLITECHNIKA WARSZAWSKA · WarszawaПолша
- Special Hospital for Surgical Diseases Zan Mitrev, Skopje · SkopjeСеверна Македония
- UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS · GoettingenГермания
Връзки
Данни: CORDIS, © Европейски съюз